Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. Maybe I am missing something here-I thought I had read numerous reports over the years for Cbio /Invion.
Latest was from Morgans 25/11/2013
Breathe Easy IVX has three drug assets (oral and inhaled respiratory and autoimmune) with multiple paths to market. The three Phase II clinical programs underway are FDA regulated with clear primary endpoints. There is an early partnering opportunity with the lupus program and significant valuation drivers are expected over the next 12 to 18 months. We maintain our Outperform rating.
1. INVESTMENT VIEW IVX has a significant clinical pipeline comprising two Phase II clinical trials, two pre-clinical programs for the repurposed beta blocker INV102. More recently IVX has in-licensed the intellectual property to develop inhaled Zafirlukast (to be known as INV104) which is currently being marketed as a generic drug. These programs are targeting pulmonary diseases which represent massive markets, including asthma, smoking cessation, chronic bronchitis, and cystic fibrosis. The company also has a third concurrent Phase II trial for INV103 targeting lupus. It’s an impressive portfolio given the company’s current market capitalisation. Regular newsflow from the trials should drive investor interest over the next 12 months, and positive results will see the stock price continue head higher, see the Catalyst Table below. We maintain an Outperform rating and A$0.12 target price. To derive this valuation we have reviewed a number of Australian listed life science companies with Phase II clinical programs underway. Based on this analysis IVX is significantly undervalued. We believe that any success in the trials will see our price target easily achieved. The need for additional funding can’t be ruled out and the usual risks around clinical development exist with IVX. For investors with a high risk appetite the company represents an exciting opportunity at the current share price.
To read full report go to Invion webpage.
Many posters have indicated that for 3 phase 2 trials in progress Invion is hugely undervalued.Having looked up companies Morgans have compared us to we should be sitting anywhere between 80c to $1.00 at the moment.Most only have 1 phase 2 in progress, as Morgans have stated above---
"To derive this valuation we have reviewed a number of Australian listed life science companies with Phase II clinical programs underway. Based on this analysis IVX is significantly undervalued"
W27 is correct –THIS IS HUGE.
IVX Price at posting:
8.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)